12:57 pm Versartis (VSAR)
Versartis (VSAR) is rallying 27% on some positive clinical news from the FDA. What happened is that the FDA has removed the partial clinical hold on the VSAR's Investigational New Drug Application for VRS-317. With this action, the company will proceed with the Phase 3 registration trial, called Velocity, of VRS-317 in children with GHD.
Before getting into more detail, let's take a step back and explain what Versartis does. Versartis is an endocrine-focused biopharma company initially developing VRS-317, a long-acting form of recombinant human …More